PEPSICO INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PEPSICO INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $93.93B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $91.85B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $91.47B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $86.39B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $79.47B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $70.37B | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | $20.64B | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | $17.19B | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | $16.45B | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | $12.88B | Feb 13, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $63.53B | Feb 13, 2018 |
| FY2017 | Dec 31, 2016 | $62.80B | Feb 13, 2018 |
| FY2017 | Dec 26, 2015 | $63.06B | Feb 13, 2018 |
| FY2016 | Dec 27, 2014 | $66.68B | Feb 15, 2017 |
| FY2015 | Dec 28, 2013 | $66.42B | Feb 11, 2016 |
| FY2014 | Dec 29, 2012 | $65.49B | Feb 12, 2015 |
| FY2013 | Dec 31, 2011 | $66.50B | Feb 14, 2014 |
| FY2012 | Dec 25, 2010 | $57.84B | Feb 21, 2013 |
| FY2011 | Dec 26, 2009 | $43.23B | Feb 27, 2012 |
| FY2010 | Dec 27, 2008 | $43.25B | Feb 18, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $50.86B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $50.11B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $49.59B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $45.82B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $42.40B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $38.58B | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | $11.29B | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | $9.49B | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | $9.05B | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | $7.20B | Feb 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $8.24B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $9.58B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $9.07B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $8.91B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $7.62B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $7.12B | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | $1.77B | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | $2.10B | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | $2.04B | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | $1.41B | Feb 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $11.50B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $12.89B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $11.99B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $11.51B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $11.16B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $10.08B | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | $2.70B | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | $2.86B | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | $2.73B | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | $2.01B | Feb 13, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $839.00M | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $813.00M | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $804.00M | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $771.00M | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $752.00M | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $719.00M | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $711.00M | Feb 10, 2022 |
| FY2020 | Dec 29, 2018 | $680.00M | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $737.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $760.00M | Feb 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $37.37B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $37.19B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $36.68B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $34.46B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $31.24B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $28.45B | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $26.74B | Feb 10, 2022 |
| FY2020 | Dec 29, 2018 | $25.17B | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $24.45B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $24.77B | Feb 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $12.09B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $12.51B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $13.44B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $10.81B | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | $11.62B | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | $10.61B | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $9.65B | Feb 10, 2022 |
| FY2020 | Dec 29, 2018 | $9.42B | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $10.03B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $10.66B | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $107.40B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $99.47B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $100.50B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $92.19B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $92.38B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $92.92B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $78.55B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $77.65B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $79.80B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $73.49B | Feb 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $86.85B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $81.30B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $81.86B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $74.91B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $76.23B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $79.37B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $63.68B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $63.05B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $68.82B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $62.29B | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $20.41B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $18.04B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $18.50B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $17.15B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $16.04B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $13.45B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $14.79B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $14.52B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $11.05B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $11.25B | Feb 13, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $18.92B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $17.53B | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | $17.73B | Feb 3, 2026 |
| FY2023 | Dec 31, 2022 | $18.20B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $18.38B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $18.76B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $15.50B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $14.81B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $14.74B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $14.43B | Feb 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $72.79B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $72.27B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $70.04B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $67.80B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $65.17B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $63.44B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $61.95B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $59.95B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $52.84B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $52.52B | Feb 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $9.16B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $8.51B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $9.71B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $4.95B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $5.60B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $8.19B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $5.51B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $8.72B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $10.61B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $9.16B | Feb 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $46.35B | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | $41.23B | Feb 3, 2026 |
| FY2024 | Dec 30, 2023 | $41.52B | Feb 4, 2025 |
| FY2023 | Dec 31, 2022 | $38.75B | Feb 9, 2024 |
| FY2022 | Dec 25, 2021 | $39.90B | Feb 9, 2023 |
| FY2021 | Dec 26, 2020 | $43.73B | Feb 10, 2022 |
| FY2020 | Dec 28, 2019 | $32.00B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $32.25B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $37.82B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $34.45B | Feb 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 6 | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | 6 | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | 6 | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | 5 | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | 5 | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | 1 | Feb 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 6 | Feb 3, 2026 |
| FY2025 | Dec 28, 2024 | 6 | Feb 3, 2026 |
| FY2025 | Dec 30, 2023 | 6 | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 4, 2025 |
| FY2023 | Dec 25, 2021 | 5 | Feb 9, 2024 |
| FY2022 | Dec 26, 2020 | 5 | Feb 9, 2023 |
| FY2019 | Dec 28, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 7, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Jun 15, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Mar 23, 2019 | 1 | Feb 13, 2020 |